Investor Alert from Former Louisiana Attorney General: Kahn Swick & Foti, LLC Examines Price and Process in iTeos Therapeutics, Inc. Sale - ITOS
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Aug 19 2025
0mins
Source: Globenewswire
Investigation Announcement: Former Louisiana Attorney General Charles C. Foti, Jr. and Kahn Swick & Foti, LLC are investigating the proposed sale of iTeos Therapeutics, Inc. to Concentra Biosciences, LLC.
Transaction Details: Shareholders of iTeos would receive $10.047 in cash per share, along with a contingent value right related to the company's net cash and product candidates.
Adequacy Concerns: KSF is assessing whether the proposed consideration adequately values iTeos and the process leading to this transaction.
Legal Rights Information: Interested parties can contact KSF for discussions regarding their legal rights related to the sale, emphasizing the urgency due to the tender offer structure.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
